Efalizumab is a targeted T cell modulator, and is a humanized monoclonal antibody ofCD11a, the α subunit of LFA-1. Efalizumab inhibits T cell activation, cutaneous T cell trafficking, and T cell adhesion to keratinocytes, can be used for plaque psoriasis research^[1].

Efalizumab (78 ng/mL-5 mg/mL) induces a leukocytosis and downregulates LFA-1 expression on T cells in the peripheral blood^[3].
Efalizumab (78 ng/mL-5 mg/mL) downregulates plate-bound, anti-CD3-stimulated proliferation of PBMC^[3].

Efalizumab shows side effects include bacterial sepsis, viral meningitis, invasive fungal disease and progressive multifocal leukoencephalopathy (PML), a brain infection caused by reactivation of latent JC virus infection^[2].

214745-43-4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.